{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:13:57Z","timestamp":1778130837435,"version":"3.51.4"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Primary central nervous system lymphoma (PCNSL) is a rare but aggressive diffuse large B-cell lymphoma confined to the CNS, characterized by unique clinical behavior and therapeutic challenges. Outcomes have improved with high-dose methotrexate (HD-MTX)-based regimens, but relapse, treatment toxicity, and age-related frailty remain major barriers. This review synthesizes advances in prognostic stratification and treatment of PCNSL. We highlight two validated clinical models (IELSG and MSKCC) and emerging genomic biomarkers that refine risk assessment. HD-MTX-based induction (MTR, R-MPV, MATRix, R-MBVP) is the standard first-line approach for fit patients, including many older adults. Consolidation with thiotepa-based high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) yields durable disease control in eligible patients, whereas non-myeloablative cytarabine-based chemotherapy or reduced-dose whole-brain radiotherapy remains an option for those unfit for transplant. In relapsed disease, methotrexate rechallenge benefits prior responders, while BTK- or IMiD-based regimens, CAR-T therapy, and focal or whole-brain radiotherapy are under active investigation. Maintenance with HD-MTX or targeted agents shows promise but requires validation. Although therapeutic outcomes have steadily improved, particularly with HD-MTX-based induction and HDC-ASCT consolidation, long-term survival for elderly and relapsed patients remains unsatisfactory. The integration of molecular biomarkers, neurotoxicity-sparing consolidation, and novel immunotherapies may further individualize treatment and improve the durability of remission.<\/jats:p>","DOI":"10.3389\/fonc.2026.1591328","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:50:13Z","timestamp":1778129413000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Translating advances in primary central nervous system lymphoma: from prognostic stratification to treatment innovation"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhenjiang","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Shanghai Shidong Hospital of Yangpu District","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shanghai Shidong Hospital of Yangpu District","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shepeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shanghai Shidong Hospital of Yangpu District","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1002\/hem3.89","article-title":"Primary central nervous system lymphomas: EHA\u2013ESMO clinical practice guideline for diagnosis, treatment, and follow-up","volume":"8","author":"Ferreri","year":"2024","journal-title":"Hemasphere"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17588359241259010","DOI":"10.1177\/20406207241259010","article-title":"Updates of primary central nervous system lymphoma","volume":"16","author":"Wu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npag016","article-title":"Primary central nervous system lymphoma \u2013 current standards and recent developments","author":"van der Meulen","year":"2026","journal-title":"Neuro-Oncology Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11912-026-01756-9","article-title":"An update on treatments for recurrent primary central nervous system lymphoma","volume":"28","author":"Friedman","year":"2026","journal-title":"Curr Oncol Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014460","article-title":"Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma","volume":"9","author":"Geng","year":"2025","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.5.689","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(01)01639-x","article-title":"Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate","volume":"51","author":"Reni","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051459","article-title":"A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma","volume":"15","author":"Villanueva","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad224","article-title":"Survival, neurocognitive function, and health-related quality-of-life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: final results of the HOVON 105\/ALLG NHL 24 study","volume":"26","author":"Bromberg","year":"2024","journal-title":"Neuro Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety, and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.7506","article-title":"Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: results of CALGB 51101 (Alliance)","volume":"39","author":"Batchelor","year":"2021","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.2501","article-title":"Randomized phase II study of rituximab, methotrexate, procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"38","author":"Omuro","year":"2020","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/10428194.2012.698736","article-title":"Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma","volume":"54","author":"Nayak","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-0032-0","article-title":"Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status","volume":"97","author":"Kurzwelly","year":"2010","journal-title":"J Neuro-Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma: a systematic review and individual-patient-data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7667","article-title":"Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma","volume":"18","author":"Holdhoff","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"Zhu","year":"2009","journal-title":"Neuro Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos153","article-title":"Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center","volume":"14","author":"Welch","year":"2012","journal-title":"Neuro Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1158\/2643-3230.BCD-24-0156","article-title":"High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase II study","volume":"6","author":"Gao","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.1534","article-title":"Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group report","volume":"71","author":"Grimm","year":"2008","journal-title":"Neurology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000776","article-title":"Primary vitreoretinal lymphoma: short review of the literature, results of a European survey, and French guidelines of the LOC network for diagnosis, treatment, and follow-up","volume":"33","author":"Malaise","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26199","article-title":"Intravenous high-dose methotrexate-based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study","volume":"96","author":"Lam","year":"2021","journal-title":"Am J Hematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-021-00506-3","article-title":"Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse","volume":"11","author":"Bobillo","year":"2021","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00365","article-title":"High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma","volume":"41","author":"Lewis","year":"2023","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.04.056","article-title":"Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","volume":"21","author":"Pels","year":"2003","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11060-008-9712-4","article-title":"Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study","volume":"91","author":"Pels","year":"2009","journal-title":"J Neuro-Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae029","article-title":"Interim FDG-PET improves treatment-failure prediction in primary central nervous system lymphoma: an LOC network prospective multicenter study","volume":"26","author":"Rozenblum","year":"2024","journal-title":"Neuro Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.13.5533","article-title":"Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire","volume":"26","author":"Soussain","year":"2008","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014373","article-title":"ICE polychemotherapy is an efficient salvage treatment in primary central nervous system lymphoma: an LOC network study","volume":"9","author":"P\u00e9rol","year":"2025","journal-title":"Blood Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-636340","article-title":"The role of autologous stem-cell transplantation in primary central nervous system lymphoma","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30695","article-title":"High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem-cell transplantation for patients with primary central nervous system lymphoma in first complete remission","volume":"123","author":"DeFilipp","year":"2017","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11771","article-title":"High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system","volume":"93","author":"Illerhaus","year":"2008","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamaoncol.2021.1074","article-title":"Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic-cell transplant","volume":"7","author":"Scordo","year":"2021","journal-title":"JAMA Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00491","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study","volume":"40","author":"Houillier","year":"2022","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03257-1","article-title":"Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem-cell transplantation","volume":"144","author":"Correa","year":"2019","journal-title":"J Neuro-Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011657","article-title":"Myeloablative versus non-myeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101","volume":"8","author":"Batchelor","year":"2024","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100102","article-title":"Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma","volume":"2","author":"Dave","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007011","article-title":"Reduced-dose whole-brain radiotherapy as consolidation treatment for patients with primary CNS lymphoma: an LOC network study","volume":"6","author":"Lesueur","year":"2022","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole-brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl464","article-title":"Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines","volume":"18","author":"Correa","year":"2007","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor186","article-title":"Cognitive functions in primary CNS lymphoma after single or combined-modality regimens","volume":"14","author":"Correa","year":"2012","journal-title":"Neuro Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab021","article-title":"Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105\/ALLG NHL 24 randomized controlled trial","volume":"23","author":"van der Meulen","year":"2021","journal-title":"Neuro Oncol"},{"key":"B57","unstructured":"NCCN clinical practice guidelines in oncology: central nervous system cancers"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immunochemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34985","article-title":"A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma","volume":"129","author":"Bairey","year":"2023","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac246","article-title":"Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with or without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C","volume":"25","author":"Mishima","year":"2023","journal-title":"Neuro Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.2500","article-title":"Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C","volume":"38","author":"Mishima","year":"2020","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014073","article-title":"Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience","volume":"9","author":"Hwang","year":"2025","journal-title":"Blood Adv"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor014","article-title":"Late relapse in primary central nervous system lymphoma: clonal persistence","volume":"13","author":"Nayak","year":"2011","journal-title":"Neuro Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","author":"Plotkin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1370-0","article-title":"Methotrexate re-challenge for recurrent primary central nervous system lymphoma","volume":"117","author":"Pentsova","year":"2014","journal-title":"J Neuro-Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.170","article-title":"High-dose\u00a0chemotherapy with autologous haematopoietic stem-cell support for relapsed or\u00a0refractory primary CNS lymphoma: a prospective multicentre trial by the German\u00a0Cooperative PCNSL study group","volume":"31","author":"Kasenda","year":"2017","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227199","article-title":"Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma","volume":"105","author":"Mika","year":"2020","journal-title":"Haematologica"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2018.02.001","article-title":"Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible","volume":"12","author":"Atilla","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.03.008","article-title":"Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial","volume":"40","author":"Reni","year":"2004","journal-title":"Eur J Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl070","article-title":"Prospective trial on topotecan salvage therapy in primary CNS lymphoma","volume":"17","author":"Fischer","year":"2006","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26709","article-title":"Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma","volume":"118","author":"Raizer","year":"2012","journal-title":"Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0489","article-title":"Pemetrexed in recurrent or progressive central nervous system lymphoma: a phase I multicenter clinical trial","volume":"25","author":"Dietrich","year":"2020","journal-title":"Oncologist"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-7506-7516-1.00009-8","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01319-x","article-title":"Tirabrutinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B82","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B-cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201cproof-of-concept\u201d phase II study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume":"30","author":"Ghesqui\u00e8res","year":"2019","journal-title":"Ann Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"B87","article-title":"Approval letter for YESCARTA (axicabtagene ciloleucel). U.S. Food and Drug Administration","year":"2026"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole-brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","author":"Hottinger","year":"2007","journal-title":"Neurology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.01.161","article-title":"Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","author":"Nguyen","year":"2005","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000207490","article-title":"Long-term outcomes in primary CNS lymphoma after R-MVP and high-dose chemotherapy with autologous hematopoietic stem cell transplant","volume":"101","author":"Therkelsen","year":"2023","journal-title":"Neurology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind: changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1591328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:50:19Z","timestamp":1778129419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1591328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":91,"alternative-id":["10.3389\/fonc.2026.1591328"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1591328","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1591328"}}